Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. | ...
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...
Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase 2 ...
Incyte Corporation is currently conducting a Phase 2 clinical study titled A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in ...
The drug, which is an NLRP3 inhibitor, also reduced other key cardiovascular risk biomarkers. Ventyx Biosciences plans to ...
ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life ...
(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...
The published manuscript detailed the safety and efficacy results of INT230-6, Intensity’s intratumoral therapy for treating metastatic or refractory cancers. The data showed a 75% disease control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback